Novo Nordisk has formed research collaboratio with Dr Michael Schwartz, director of The Diabetes and Obesity Center of Excellence at the University of Washington (UW). The collaboration aims to understand factors mediating brain control of blood glucose and appetite with the goal of developing new therapeutic agents for the treatment of diabetes and obesity. The research will be conducted at UW Medicine’s South Lake Union research campus in Seattle, Washington, and at Novo Nordisk.

Over the next three years, Michael W Schwartz, MD, a University of Washington professor of medicine, his team, and Novo Nordisk researchers will conduct a research program on the effect of known hormonal factors working in the brain to regulate whole body glucose metabolism and appetite.

Source: Novo Nordisk